Safety of long-term PPI therapy

被引:90
作者
Reimer, Christina [1 ]
机构
[1] Hvidovre Univ Hosp, Dept Gastroenterol, DK-2650 Hvidovre, Denmark
关键词
Proton pump inhibitors; Safety; Bone fractures; Malabsorption; Clostridium difficile; Salmonella; Campylobacter jejuni; Pneumonia; Neoplasms; Congenital abnormalities; Mortality; PROTON-PUMP INHIBITORS; HELICOBACTER-PYLORI INFECTION; GASTROESOPHAGEAL-REFLUX DISEASE; COMMUNITY-ACQUIRED PNEUMONIA; ACID SUPPRESSIVE THERAPY; BONE-MINERAL DENSITY; GASTRIC-ACID; OMEPRAZOLE THERAPY; RISK-FACTORS; CAMPYLOBACTER GASTROENTERITIS;
D O I
10.1016/j.bpg.2013.06.001
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Proton pump inhibitors have become the mainstay of medical treatment of acid-related disorders. Long-term use is becoming increasingly common, in some cases without a proper indication. A large number of mainly observational studies on a very wide range of possible associations have been published in the past decade. and are critically reviewed in this article and the existing evidence is evaluated and translated into possible clinical consequences. Based on the existing evidence the benefits of PPI treatment seem to outweigh potential risks in the large majority of patients especially if PPI use is based on a relevant indication. The concern for complications should primarily be directed at elderly, malnourished with significant co-morbidity. In this population an increased risk for enteric infections, fractures and nutritional deficiencies might have clinical consequences and should lead to a careful evaluation of the indication for PPI treatment. (c) 2013 Elsevier Ltd. All rights reserved.
引用
收藏
页码:443 / 454
页数:12
相关论文
共 81 条
[31]  
IMS, IMS HLTH REP 2013
[32]   Increased risk of fundic gland polyps during long-term proton pump inhibitor therapy [J].
Jalving, M. ;
Koornstra, J. J. ;
Wesseling, J. ;
Boezen, H. M. ;
De Jong, S. ;
Kleibeuker, J. H. .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2006, 24 (09) :1341-1348
[33]   Clostridium difficile-Associated Diarrhea and Proton Pump Inhibitor Therapy: A Meta-Analysis [J].
Janarthanan, Sailajah ;
Ditah, Ivo ;
Adler, Douglas G. ;
Ehrinpreis, Murray N. .
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2012, 107 (07) :1001-1010
[34]   Meta-analysis: proton pump inhibitor use and the risk of community-acquired pneumonia [J].
Johnstone, J. ;
Nerenberg, K. ;
Loeb, M. .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2010, 31 (11) :1165-1177
[35]   On-demand requirements of patients with endoscopy-negative gastro-oesophageal reflux disease: H2-blocker vs. proton pump inhibitor [J].
Juul-Hansen, P. ;
Rydning, A. .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2009, 29 (02) :207-212
[36]   Proton pump inhibitor use and risk of hip fractures in patients without major risk factors [J].
Kaye, James A. ;
Jick, Hershel .
PHARMACOTHERAPY, 2008, 28 (08) :951-959
[37]   Long-term omeprazole treatment in resistant gastroesophageal reflux disease:: Efficacy, safety, and influence on gastric mucosa [J].
Klinkenberg-Knol, EC ;
Nelis, F ;
Dent, J ;
Snel, P ;
Mitchell, B ;
Prichard, P ;
Lloyd, D ;
Havu, N ;
Frame, MH ;
Romàn, J ;
Walan, A .
GASTROENTEROLOGY, 2000, 118 (04) :661-669
[38]   Proton pump inhibitors and gastric neoplasia [J].
Kuipers, E. J. .
GUT, 2006, 55 (09) :1217-1221
[39]   Atrophic gastritis and Helicobacter pylori infection in patients with reflux esophagitis treated with omeprazole or fundoplication [J].
Kuipers, EJ ;
Lundell, L ;
KlinkenbergKnol, EC ;
Havu, N ;
Festen, HPM ;
Liedman, B ;
Lamers, CBHW ;
Jansen, JBMJ ;
Dalenback, J ;
Snel, P ;
Nelis, GF ;
Meuwissen, SGM .
NEW ENGLAND JOURNAL OF MEDICINE, 1996, 334 (16) :1018-1022
[40]   Risk of Clostridium difficile Infection With Acid Suppressing Drugs and Antibiotics: Meta-Analysis [J].
Kwok, Chun Shing ;
Arthur, Aaron Kobina ;
Anibueze, Chukwudubem Ifeanyichukwu ;
Singh, Sonal ;
Cavallazzi, Rodrigo ;
Loke, Yoon Kong .
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2012, 107 (07) :1011-1019